Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy (TARGET-FIRST)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519854-35-00

Acronym

SFHI01

Enrollment

695

Registered

2025-01-15

Start date

2021-06-29

Completion date

2025-03-24

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

Net Adverse Clinical and Cerebral Events (NACCE) defined as a composite of all cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 11 months post randomization (12 months post index procedure).

Detailed description

The main secondary endpoint is BARC type 2, 3 or 5 bleeding events at 11 months post-randomization.

Interventions

DRUGEfient 10 mg film-coated tablets.

DRUGBrilique 90 mg film-coated tablets

DRUGASPIRINE PROTECT 100 mg

DRUGcomprimé gastro-résistant

DRUGPlavix 75 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Net Adverse Clinical and Cerebral Events (NACCE) defined as a composite of all cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 11 months post randomization (12 months post index procedure).	—

Secondary

Measure	Time frame
The main secondary endpoint is BARC type 2, 3 or 5 bleeding events at 11 months post-randomization.	—

Countries

Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026